HomeCompareSBGSF vs ABBV

SBGSF vs ABBV: Dividend Comparison 2026

SBGSF yields 1.05% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $44.5K in total portfolio value
10 years
SBGSF
SBGSF
● Live price
1.05%
Share price
$270.88
Annual div
$2.83
5Y div CAGR
52.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.8K
Annual income
$15,521.63
Full SBGSF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — SBGSF vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSBGSFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SBGSF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SBGSF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SBGSF
Annual income on $10K today (after 15% tax)
$88.96/yr
After 10yr DRIP, annual income (after tax)
$13,193.39/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ABBV beats the other by $7,862.62/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SBGSF + ABBV for your $10,000?

SBGSF: 50%ABBV: 50%
100% ABBV50/50100% SBGSF
Portfolio after 10yr
$80.1K
Annual income
$20,146.70/yr
Blended yield
25.15%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

SBGSF
No analyst data
Altman Z
4.5
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SBGSF buys
0
ABBV buys
0
No recent congressional trades found for SBGSF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSBGSFABBV
Forward yield1.05%3.06%
Annual dividend / share$2.83$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR52.7%40.6%
Portfolio after 10y$57.8K$102.3K
Annual income after 10y$15,521.63$24,771.77
Total dividends collected$34.6K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: SBGSF vs ABBV ($10,000, DRIP)

YearSBGSF PortfolioSBGSF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,860$159.81$11,550$430.00$690.00ABBV
2$11,868$247.67$13,472$627.96$1.6KABBV
3$13,085$386.26$15,906$926.08$2.8KABBV
4$14,608$607.75$19,071$1,382.55$4.5KABBV
5$16,599$968.33$23,302$2,095.81$6.7KABBV
6$19,331$1,570.23$29,150$3,237.93$9.8KABBV
7$23,294$2,609.73$37,536$5,121.41$14.2KABBV
8$29,413$4,487.84$50,079$8,338.38$20.7KABBV
9$39,559$8,086.83$69,753$14,065.80$30.2KABBV
10$57,849$15,521.63$102,337$24,771.77$44.5KABBV

SBGSF vs ABBV: Complete Analysis 2026

SBGSFStock

Schneider Electric S.E. provides energy and automation digital solutions worldwide. It operates through two segments, Energy Management and Industrial Automation. The company offers busway and cable support products, circuit breakers and switches, contactors and protection relays, electrical protection and control products, energy management software solutions, transfer switches, surge protection and power conditioning products, power monitoring and control products, power quality and power factor correction products, pushbuttons, switches, pilot lights and joysticks, software products, and switchboards and enclosures. It also provides access control, building management, fire detection, sensors and room units, valve and valve actuator, and variable and frequency speed drive. In addition, the company offers feeder automation, grid automation and SCADA software products, medium voltage switchgears and transformers, outdoor equipment, substation automation products, and switchgear components. Further, it provides critical power and cooling services, data center software, IT power distribution products, prefabricated data center modules, racks and accessories, and security and environmental monitoring products; home automation and security, installation materials and systems, light switches and electrical sockets, and uninterruptible power supply products; and human machine interface, industrial automation software, industrial communication, measurement and instrumentation, motion control and robotics, signaling units, programmable logic and automation controllers, power supply and protection, process control and safety, RFID systems, signaling devices, and other industrial automation and control products, as well as solar and energy storage. The company was founded in 1836 and is headquartered in Rueil-Malmaison, France.

Full SBGSF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this SBGSF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SBGSF vs SCHDSBGSF vs JEPISBGSF vs OSBGSF vs KOSBGSF vs MAINSBGSF vs JNJSBGSF vs MRKSBGSF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.